MCT1 is a Predictive Marker for Lenalidomide Maintenance Therapy in Multiple Myeloma.Jacob Stroh,Anja Seckinger,Michael Heider,Ruth Eichner,Martina Emde,Hans Salwender,Uta Bertsch,Hartmut Goldschmidt,Katja Weisel,Christof Scheid,Dirk Hose,Florian BassermannBlood Advances（2021）引用 5|浏览5关键词International Myeloma Working GroupAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
